

PATENT

IN UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 7,491,799 B2

Docket No: 17355CIP3(BOT)

Issue Date: February 17, 2009

Patentee: Lance E. Steward et al.

Title MODIFIED BOTULINUM NEUROTOXINS

REQUEST FOR CERTIFICATION OF CORRECTION

Attn: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. Two copies of the text of the Certificate in the suggested form are enclosed.

Pursuant to 1.20(a), the examiner is authorized to charge the Certificate of Correction fee of \$100.00 to the Deposit Account No. 01-0885.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims as properly allowed, and re-examination is not required.

The Examiner is authorized to charge any additional fees or credit overpayment to Deposit Account No. 01-0885.

Respectfully submitted,

/Dean G. Stathakis/

Date: April 17, 2009

Attorney Name: Dean G. Stathakis
Reg. No.: 54,465

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,491,799

DATED : February 17, 2009

INVENTOR(S) : Steward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face page, in field (56), under "Other Publications", in column 2, line 21, delete "botullsm" and insert - - botulism - -, therefor.

The Drawings: Original Figures submitted on January 14, 2004 were replaced with substitute clean drawings on February 1, 2007 (**see first 37 pages**). **The Examiner annotated on Eban on April 14, 2009.**

In column 1, line 23, delete "botulinum" and insert - - Botulinum - -, therefor.

In column 1, line 26, delete "botulinum" and insert - - Botulinum - -, therefor.

In column 6, line 39, delete "derivativization" and insert --derivatization--, therefor.

In column 7, line 57, delete "caseine" and insert -- casein --, therefor.

In column 8, line 5, delete "caseine" and insert -- casein --, therefor.

In column 8, line 56, delete "caseine" and insert -- casein --, therefor.

In column 10, line 63, below "membrane." insert - - Fig. 6 shows an x-ray crystallographic structure of botulinum toxintype A. - -.

In column 11, line 65, delete "Light Chain" and insert - - light chain - -, therefor.

In column 12, line 8, delete "Light Chains" and insert - - light chains - -, therefor.

In column 14, line 14, after "18)" insert - - , - -.

In column 15, line 31, delete "B." and insert - - B, - -, therefor.

MAILING ADDRESS OF SENDER:

Allergan, Inc.
Dean G. Stathakis (T2-7H)
2525 Dupont Drive
Irvine, California 92612

PATENT NO. 7,491,799
Atty Docket No: 17355CIP3(BOT)

No. of additional copies

⇒ _____

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,491,799

DATED : February 17, 2009

INVENTOR(S) : Steward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 18, line 65, delete "HAIIA" and insert - - HAIIA - -, therefor.

In column 20, line 1, delete "botulinumtoxin" and insert - - botulinum toxin- -, therefor.

In column 20, line 21, delete "botulinum" and insert - - Botulinum - -, therefor.

In column 28, line 64, delete "MgCl2" and insert - - MgCl₂ - -, therefor.

In column 30, line 4, delete "CaCl2" and insert - - CaCl₂ - -, therefor.

In column 33, line 43, after "botulinum" insert - - . - -.

In column 34, line 40, delete "(Stemberger)" and insert --(Sternberger)--, therefor.

In column 35, line 31, delete "(Stemberger)" and insert --(Sternberger)--, therefor.

In column 35, line 34, after "mutants" insert - - . - -.

In column 43, line 24, delete "EC₅₀rLC/A(LL-->AA)" and insert - - EC₅₀rLC/A(LL-->AA) - -, therefor.

In column 43, line 28, delete "C1" and insert --C₁--, therefor.

In column 45, line 41, delete "RGIVDRLNKVLVCISDPNINININIKNKEKDKEYKFVED" and insert - - RGIVDRLNKVLVCISDPNINININIKNFKDKYKFVED - -, therefor.

In column 46, line 16, delete "KYEFLKVPNLLDDDIYTVSEGFNIGNLAVNRRGQSIKL" and insert - - KYEFLKVPNLLDDDIYTVSEGFNIGNLAVNNRRGQSIKL - -, therefor.

In column 46, line 55, delete "VLQNFRGIVDRLNKVLVCISDPNINININIKNFKDKYK" and insert - - VLQNFRGIVDRLNKVLVCISDPNINININIKNFKDKYK - -, therefor.

In column 46, line 60, delete "NMGKEYRGQNKAINKQAYEEISKEHLAVYKIQMGKSV" and insert - - NMGKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSV - -, therefor.

MAILING ADDRESS OF SENDER:

Allergan, Inc.
Dean G. Stathakis (T2-7H)
2525 Dupont Drive
Irvine, California 92612

PATENT NO. 7,491,799
Atty Docket No: 17355CIP3(BOT)

No. of additional copies



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,491,799

DATED : February 17, 2009

INVENTOR(S) : Steward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 48, line 26, delete "MPVTINN**FN**MPFVNKQFNYKDPVNGVDIAYIKIPNAG" and insert - - MPVTINN**FN**MPFVNKQFNYKDPVNGVDIAYIKIPNAG - -, therefor.

In column 49, line 26, delete "sterotypes," and insert - - serotypes, - -, therefor.

In column 50, line 50, delete "C1" and insert --C₁--, therefor.

In column 51, line 15, delete "C1" and insert --C₁--, therefor.

In column 51, line 25, delete "C1" and insert --C₁--, therefor.

In column 51, line 36, delete "C1" and insert --C₁--, therefor.

In column 51, line 63, delete "LCA-GFP-GFP" and insert - - LCA-GFP - -, therefor.

In column 51, line 66, delete "LCE-GFP-GFP" and insert - - LCE-GFP - -, therefor.

In column 52, line 2, delete "LCB-GFP-GFP" and insert - - LCB-GFP - -, therefor.

In column 52, line 3, delete "LCB-GFP-GFP" and insert - - LCB-GFP - -, therefor.

In column 52, line 7, delete "LCB-GFP-GFP" and insert - - LCB-GFP - -, therefor.

In column 52, line 8, delete "LCB-GFP-GFP" and insert - - LCB-GFP - -, therefor.

In column 52, line 10, delete "LCB-GFP-GFP" and insert - - LCB-GFP - -, therefor.

MAILING ADDRESS OF SENDER:

Allergan, Inc.
Dean G. Stathakis (T2-7H)
2525 Dupont Drive
Irvine, California 92612

PATENT NO. 7,491,799
Atty Docket No: 17355CIP3(BOT)

No. of additional copies



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,491,799

DATED : February 17, 2009

INVENTOR(S) : Steward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 52, line 41, after "expression" insert - - . - -.

In column 52, line 55, delete "(Stemberger)" and insert --(Sternberger)--, therefore.

In column 56, line 40, delete "³H-noradrenline" and insert - -³H-noradrenaline - -, therefor.

In column 57, line 1, delete "permbealized" and insert - - permeabilized - -, therefor.

In column 57, line 7, delete "³H- norepinephorine" and insert - - ³H- norepinephrine - -, therefor.

MAILING ADDRESS OF SENDER:

Allergan, Inc.
Dean G. Stathakis (T2-7H)
2525 Dupont Drive
Irvine, California 92612

PATENT NO. 7,491,799
Atty Docket No: 17355CIP3(BOT)

No. of additional copies

